Citigroup Inc Argenx Se Call Options Transaction History

Citigroup Inc

  • $169 Billion
  • Q3 2024

Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 12, 2024
BUY
$434.22 - $551.9 $9.94 Million - $12.6 Million
22,900 New
22,900 $12.4 Million
Q1 2024

May 10, 2024
SELL
$356.95 - $413.29 $6.85 Million - $7.94 Million
-19,200 Reduced 64.0%
10,800 $4.25 Million
Q4 2023

Feb 09, 2024
BUY
$338.91 - $506.01 $813,384 - $1.21 Million
2,400 Added 8.7%
30,000 $11.4 Million
Q3 2023

Nov 09, 2023
BUY
$369.35 - $548.43 $10.2 Million - $15.1 Million
27,600 New
27,600 $13.6 Million

Others Institutions Holding ARGX

# of Institutions
400
Shares Held
30.9M
Call Options Held
376K
Put Options Held
489K
View Full List

About ARGENX SE

ARGX Quotes by TradingView
  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.5B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email